Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

52 trials with published results (24%)

Research Maturity

147 completed trials (69% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.3%

5 terminated out of 214 trials

Success Rate

96.7%

+10.2% vs benchmark

Late-Stage Pipeline

29%

61 trials in Phase 3/4

Results Transparency

35%

52 of 147 completed with results

Key Signals

52 with results97% success

Data Visualizations

Phase Distribution

191Total
Not Applicable (66)
Early P 1 (1)
P 1 (18)
P 2 (45)
P 3 (45)
P 4 (16)

Trial Status

Completed147
Unknown28
Recruiting14
Not Yet Recruiting10
Terminated5
Withdrawn4

Trial Success Rate

96.7%

Benchmark: 86.5%

Based on 147 completed trials

Clinical Trials (214)

Showing 20 of 20 trials
NCT07025811Phase 4Active Not RecruitingPrimary

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

NCT05514041Phase 4CompletedPrimary

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05586152Phase 1CompletedPrimary

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

NCT07540884Not ApplicableNot Yet RecruitingPrimary

Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops

NCT06544694Phase 3CompletedPrimary

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

NCT07140380Phase 2CompletedPrimary

Phase 2b Controlled Study

NCT06660290Phase 3CompletedPrimary

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

NCT07469865Not ApplicableCompletedPrimary

Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)

NCT07128628Phase 2RecruitingPrimary

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

NCT07284381Phase 3RecruitingPrimary

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07238699Not ApplicableRecruitingPrimary

An Evaluation of the Safety and Tolerability of Ocular Lubricants

NCT07457021Not Yet RecruitingPrimary

A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)

NCT06444516Not ApplicableCompletedPrimary

Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease

NCT07264517Phase 2RecruitingPrimary

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

NCT06244316Phase 2CompletedPrimary

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

NCT06400459Phase 1CompletedPrimary

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

NCT06544707Phase 3CompletedPrimary

A Study Designed to Evaluate Tear Production

NCT07363824RecruitingPrimary

A Study on the Correlation Between Tear Iron Levels and the Severity of Dry Eye Disease.

NCT05865457Not ApplicableRecruitingPrimary

Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease

NCT05865379Not ApplicableRecruitingPrimary

Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease

Scroll to load more

Research Network

Activity Timeline